Drug Research
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta T-cells to develop transformational immunotherapies, announced the formation of a spin-out...
Clinical Trials
Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
Replimune Group Inc. , a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, announced that the first patient has been enrolled...
Press Releases
Alexion and Stealth Announce Agreement for develop and Commercialize Late Stage Therapy for Mitochondrial Diseases
Alexion Pharmaceuticals, Inc. and Stealth BioTherapeutics Corp announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated...
Drug Research
Insilico Medicine and ChemDiv form a strategic drug discovery service alliance
Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. This collaboration...
News
Sanofi Opens Its First Digital Manufacturing Facility in Massachusetts
Paris-based Sanofi announced it has inaugurated the opening of its first new digital manufacturing facility for biologics production in Framingham, Massachusetts. The digital-enabled aspect...
Industry Reports
Thermo Fisher Scientific Completes Acquisition of GSK Manufacturing Site in Cork, Ireland
Thermo Fisher Scientific Inc, the world leader in serving science, has completed its previously announced acquisition of an active pharmaceutical ingredient (API) manufacturing facility...
Drug Research
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients
Bayer AG and its development partner Janssen Research & Development, LLC announced that the U.S. FDA has approved rivaroxaban (Xarelto) for the prevention of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read